A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid / Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

Status: Active


The purpose of this study is to evaluate the efficacy and safety of pemigatinib (INCB054828) in subjects with myeloid / lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1 rearrangement.

Eligibility Criteria

Inclusion Criteria

  • Documented lymphoid or myeloid neoplasm with 8p11 rearrangement known to lead to FGFR1 activation, based on standard diagnostic cytogenetic evaluation performed locally, before signing informed consent for this study.
  • Eligible subjects must:
  • Have relapsed after stem cell transplantation or after other disease modifying therapy, OR
  • Not be current candidates for stem cell transplantation or other disease modifying therapies.
  • Note: All relapsed/refractory subjects must have evidence of either cytogenetic or hematological disease and have no evidence of residual toxicity (eg, graft-versus-host disease requiring treatment).
  • Life expectancy ≥ 12 weeks.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

Exclusion Criteria

  • Prior receipt of a selective FGFR inhibitor.
  • History and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, except calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcifications.
  • Current evidence of corneal disorder/keratopathy, including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, and keratoconjunctivitis, as confirmed by ophthalmologic examination.
  • Use of any potent cytochrome P450 3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug.

Locations & Contacts


City of Hope Comprehensive Cancer Center
Status: Active
Name Not Available
Palo Alto
Stanford Cancer Institute Palo Alto
Status: Active
Name Not Available


Emory University Hospital / Winship Cancer Institute
Status: Active
Name Not Available


Saint Louis
Siteman Cancer Center at Washington University
Status: Active
Name Not Available


M D Anderson Cancer Center
Status: Active
Name Not Available

Trial Phase & Type

Trial Phase

Phase II

Trial Type


Lead Organization

Lead Organization
Incyte Corporation

Trial IDs

Primary ID INCB 54828-203
Secondary IDs NCI-2017-00141
Clinicaltrials.gov ID NCT03011372